Amneal Pharmaceuticals (AMRX) Misses Q3 EPS by 5c; Offers FY22 Guidance

Amneal Pharmaceuticals (: AMRX) reported Q3 EPS of $0.14, $0.05 worse than the analyst estimate of $0.19. Revenue for the quarter came in at $546 million versus the consensus estimate of $564.24 million.

GUIDANCE:

Amneal Pharmaceuticals sees FY2022 EPS of $0.65-$0.70, versus the consensus of $0.68. Amneal Pharmaceuticals sees FY2022 revenue of $2.15-2.25 billion, versus the consensus of $2.2 billion.

For earnings history and earnings-related data on Amneal Pharmaceuticals (AMRX) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Goldman reinstates Estee Lauder rating, sees turnaround driving growth and margins
• Accenture downgraded by TD Cowen on AI concerns